ALMDP Share Price Performance
€0.35
-0.01 (-1.96%)
Price €0.35
Share Pricen/a
Medesis Pharma S.A. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
ALMDP Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Medesis Pharma S.A. Key Details
Last Reported Earnings
Jun 30, 2024
Next Reporting Earnings
n/a
- -0.62
- -3,244.94%
- -4,924.73%
- -64.7%
About ALMDP
- Founded
- 2003
- Employees
- 10
- CEO
- WebsiteView website
Medesis Pharma S.A. operates as a biopharmaceutical company. The company’s products include NanoLithium (NP03) for the treatment of Alzheimer’s disease; NanosiRNA HD and NanoP42T to treat Huntington’s disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nuclear drugs. It also develops oncology drugs, including NanosiRNA IFNAR and NanoManganese Radiotherapy Glioblastoma. The company was founded in 2003 and is based in Montpellier, France.
